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ABSTRACT
School-entry requirements in the US have led to high coverage for several vaccines, but few states and
jurisdictions have adopted these policies for human papillomavirus (HPV) vaccination. Because physicians
play a key role in advocating for vaccination policies, we assessed physician support of requiring HPV
vaccine for school entry and correlates of this support. Participants were a national sample of 775
physicians who provide primary care, including vaccines, to adolescents. Physicians completed an online
survey in 2014 that assessed their support for school-entry requirements for HPV vaccination of 11 and 12
y olds. We used multivariable logistic regression to assess correlates of support for these requirements.
The majority of physicians (74%) supported some form of school-entry requirements, with or without opt-
out provisions. When opt-out provisions were not specified, 47% agreed that laws requiring HPV
vaccination for school attendance were a “good idea.” Physicians more often agreed with requirements,
without opt-out provisions, if they: had more years in practice (ORD1.49; 95% CI: 1.09-2.04), gave higher
quality HPV vaccine recommendations (ORD2.06; 95% CI: 1.45-2.93), believed that having requirements
for Tdap, but not HPV, vaccination undermined its importance (ORD3.33; 95% CI: 2.26-4.9), and believed
HPV vaccination was as or more important than other adolescent vaccinations (ORD2.30; 95% CI: 1.65-
3.18). In conclusion, we found that many physicians supported school-entry requirements for HPV
vaccination. More research is needed to investigate the extent to which opt-out provisions might weaken
or strengthen physician support of HPV vaccination school-entry requirements.
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Introduction
Human papillomavirus (HPV) is responsible for almost all cer-
vical cancers, and will affect an estimated 12,900 US women in
2015 and lead to 4,100 deaths.1 Persistent HPV infections also
cause a significant proportion of other cancers in both men and
women, including oropharyngeal and several anogenital can-
cers.2 Most HPV-associated cancers are caused by types 16 and
18; as HPV vaccines are highly protective against these strains,
most HPV-associated cancers could potentially be prevented.3,4
The Advisory Committee on Immunization Practices (ACIP)
recommends that children ages 11-12 routinely receive 3 doses
of HPV vaccine, with catch-up vaccination until age 21 for
males and 26 for females.5 Despite these recommendations,
that are based on the demonstrated efficacy and safety of HPV
vaccination,6-9 coverage is low in the US. In 2014, only 40% of
females and 22% of males ages 13-17 had received all 3 doses of
HPV vaccine.10 These coverage levels were substantially lower
than for other adolescent vaccines, such as tetanus, diphtheria
and pertussis (Tdap) that had coverage of 88%.10
One factor that, in part, accounts for the differences in ado-
lescent vaccine coverage is that most states have school-entry
requirements for Tdap vaccination but not HPV vaccination.11
Immunization requirements for school entry have led to high
coverage rates for many other vaccines in the US, including
Tdap, measles, mumps and rubella (MMR), polio, haemophilus
(Hib), varicella, and hepatitis B vaccines.11-13 The Task Force
on Community Preventive Services recommends school-entry
requirements to increase vaccination coverage in children.14
Although about half of US states have at some point proposed
legislation requiring HPV vaccination for school entry, such a
requirement has come into effect only in Virginia and the Dis-
trict of Columbia through legislation, and more recently in
Rhode Island through a state health department rule.15 Laws in
Virginia and Washington DC include an opt-out clause, which
might lessen their impact on coverage.16
Previous studies conducted in 5 southeastern North Caro-
lina counties and in Los Angeles, California reported that 46%
and 59% of parents of adolescents supported HPV vaccine
school-entry requirements, respectively.17-18 These studies also
reported that support increased when the requirements
included opt-out provisions. However, one potential negative
consequence of opt-out provisions for HPV vaccination is
parents requesting exemptions for other adolescent vaccines,
which may contribute to a culture of vaccination refusal.16 If
so, opt-out provisions may undermine school-entry vaccination
requirements.
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Data are currently limited regarding physicians’ attitudes
about such school-entry vaccination requirements with or
without opt-out provisions. Adopting school-entry vaccina-
tion requirements usually requires a broad coalition, includ-
ing legislators, state health departments, and immunization
champions, with physicians often leading or playing key
roles in these efforts. Opposition from physician groups can
slow or derail adoption of policies, such as pharmacist pro-
vision of HPV vaccination.19,20 Better understanding of phy-
sician attitudes about HPV vaccination requirements can
inform states’ policy-related efforts. Our study sought to
assess the acceptability of HPV vaccination school-entry
requirements among a national sample of physicians,
describe correlates of physician support for such require-
ments, and evaluate the effect of including opt-out
provisions on support.
Results
Approximately half of the surveyed physicians were pediatri-
cians (53%) and had been in practice for at least 20 y (55%)
(Table 1). The majority were in private practices (85%), saw 10
or more adolescent patients per week (83%), and provided 10%
or more vaccine doses through the Vaccine for Children (VFC)
program (55%). Fewer than 10% were in practices that did not
stock HPV vaccine regularly, and about 12% practiced in clinics
that had a policy allowing dismissal of patients or families that
continued to refuse recommended vaccines.
Overall, 47% of physicians agreed with the general statement
that laws requiring HPV vaccination for school attendance are
a good idea (Table 2). When asked whether such laws were
only okay if parents are able to opt out, 18% supported school-
entry requirements only without opt-out provisions (agree to “I
think these laws are a good idea” and disagree to “okay only if
parents can opt out”), while 8% switched to neither agree nor
disagree. Forty seven percent of physicians agreed with the
statement that it is okay to have these laws if parents can opt
out if they want to. Eighteen percent of physicians supported
school-entry requirements only with opt-out provisions (dis-
agree to “I think these laws are a good idea” and agree to “okay
only if parents can opt out”). In total, 74% of physicians agreed
with at least one statement of support for school-entry require-
ments (either with or without opt-out provisions), and only
12% of physicians did not support such requirements under
any circumstances (disagree to both statements).
In multivariate analyses, 4 variables were associated with
agreement that HPV vaccine requirement laws “are a good
idea” (Table 3). Physicians who had been in practice longer
(20 years) more often agreed with these laws than physicians
who had been in practice for less time (ORD1.49, 95% CI,
1.09-2.04). Support for these laws was more common among
physicians who described giving high-quality HPV vaccine rec-
ommendations (ORD2.06, 95% CI, 1.45-2.93) and those who
rated the importance of HPV vaccine as at least on par with
Tdap and meningococcal vaccines (ORD2.30, 95% CI, 1.65-
3.18). Support was also more common among physicians who
agreed that having a requirement for Tdap vaccine, but not for
HPV vaccine, undermined the importance of immunization
against HPV (ORD 3.33, 95% CI, 2.26-4.90).
Bivariate analyses found support for HPV vaccination
school-entry requirements correlated with a “presumptive”
style of recommendation, meaning that physicians began con-
versations about HPV vaccine with a statement that the child
was due for the vaccine, rather than eliciting questions or giving
information. Support of having trained pharmacists deliver
HPV vaccines also correlated with support of school-entry
requirements for HPV vaccination. However, neither variable
remained statistically significant in multivariable analysis.
Discussion
Physicians are highly respected authorities on HPV vaccina-
tion, with their recommendations being the strongest predictor
of parents’ acceptance of the vaccine for their adolescent chil-
dren.21-24 Physicians also play a key role in advocating for the
adoption of vaccination laws and policies, including school-
entry requirements. Our national study found that most pedia-
tricians and family physicians (74%) supported some form of
school-entry requirement for HPV vaccine, though the inclu-
sion of opt-out provisions played a complex role in support.
Support for school-entry HPV vaccination requirements was
higher among more experienced physicians who valued the
Table 1. Physician and practice characteristics (N D 775).
n %
Demographic characteristics
Female 250 32
Medical specialty
Pediatrics 410 53
Family medicine 365 47
Years practicing medicine
<20 years 351 45
20 years 424 55
Patients ages 11-17 seen per week
< 10 129 17
10-24 350 45
> 24 296 38
Practice characteristics
Private practice
No 115 15
Yes 650 85
Number of physicians
1 115 15
2-4 283 36
5-9 217 28
10 160 21
Vaccines provided that are financed by VFC
0-9% 290 37
10-49% 273 35
50% or greater 152 20
Not sure 60 8
Regularly stocks HPV vaccine
No 73 9
Yes 702 91
Dismisses families who continue to refuse adolescent vaccines1
No 684 88
Yes 91 12
Region
Northeast 184 24
Midwest 165 21
South 274 35
West 152 20
Note. VFCDVaccines for Children program. HPVDhuman papillomavirus
1Have a policy to dismiss patients or families who continue to refuse Tdap, menin-
gococcal, or HPV vaccination.
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vaccine, and who gave higher-quality recommendations to
patients.
Almost half (47%) of physicians supported HPV vaccination
school-entry requirements when the survey did not mention an
opt-out provision. This was slightly higher than the 42% sup-
port for “mandated HPV vaccination” in a 2008 survey of
Texas physicians25 and comparable to previous studies of US
parents when no opt-out was mentioned (46% in North Caro-
lina17 and 59% in Los Angeles18). At face value, this moderate
level of support may explain why few states have pursued such
requirements.
Previous studies of US parents have shown that mentioning
an opt-out provision for HPV vaccine school-entry require-
ments increased support to 92%, which is both promising and
problematic.18 However, we found similar support among pri-
mary care physicians (47%) regardless of opt-out provisions,
with a large number switching positions from for to against,
and vice-versa. It would appear that some physicians would
support the requirements only if there was no easy opt-out.
Opt-out provisions were legislated in 2 of the 3 states that have
HPV vaccination school-entry requirements and are likely to
be important in passing similar laws in other states.26 Our study
highlights the need to determine how different stakeholders
understand this policy language, in addition to implications for
vaccine uptake and effectiveness.
Little research has examined parents’ use of vaccination opt-
outs, exemptions and refusals to follow the requirements with
regard to HPV vaccination. A model-based study estimated
that school-entry requirements for HPV vaccination could
reduce the time it will take the US to reach 70% HPV vaccina-
tion coverage from 23 y to 8 y.27 However, while school-entry
requirements for vaccination of young children have generally
been effective in the US, they have largely failed for HPV vacci-
nation.28 It appears that allowing parents to opt-out, which
may increase acceptability and contribute to family’s auton-
omy, decreases the effectiveness of the HPV vaccination
requirements.16,29 People opting out in large numbers likely
contributed to the disappointing impact of Virginia and the
District of Columbia’s school-entry requirements on HPV vac-
cination coverage.16
While our findings offer one of the first looks at physi-
cian attitudes on HPV vaccine opt-out provisions, some
information regarding attitudes toward departures from
routine vaccination practice is available. A recent study
from Kempe and colleagues30 found that physicians often
favor parental autonomy over best practice; although 87%
of physicians felt that spreading out vaccines (including
HPV vaccine) put children at risk, 72% agreed to an alter-
native schedule to foster greater trust between physician
and family. Evidence also suggests that physicians are more
comfortable with refusals or exemptions for some vaccina-
tions than others,31 with some physicians considering HPV
vaccine to be more “optional” than other vaccines.32-34 Fur-
thermore, health care providers in Arizona had low support
(37%) for a policy requiring them to sign off on parent’s
decision to refuse vaccination.31 It would be valuable to
gather qualitative data on how physicians think about
requiring HPV vaccination as well as permissive and strict
opt-out provisions.
Correlates of support paint a picture of experienced physi-
cians who value HPV vaccine and might be good leaders and
spokespersons for advocacy efforts. In the present study, the
strongest predictor of support for HPV vaccination school-
entry requirements was recognizing the importance of consis-
tent policy and messaging (agreement that “Having a school-
entry requirement for Tdap vaccine, but not for HPV vaccine,
makes some parents think HPV vaccine is less important”);
this further suggests that physicians recognize the weight of leg-
islation in vaccine discussions with individual patients. Other
predictors include having more years in practice, believing that
HPV vaccine is as or more important than other adolescent
vaccines, and giving high-quality HPV vaccine recommenda-
tions. Although previous studies have reported that physicians
find communication about HPV vaccine can be burden-
some,25,35 neither anticipation of discomfort surrounding dis-
cussion of a sexually transmitted infection nor higher time
burden compared to other vaccines were associated with physi-
cian support of school-entry requirements. This is particularly
important because physician recommendation remains the
strongest known predictor of HPV vaccination,36 suggesting
that physician support of HPV vaccination school-entry
requirements is not expected to replace this important
discussion.
Strengths of our study include our large, national sample of
primary care physicians. Study limitations included relying on
physicians’ self-report of their clinical practices, such as HPV
Table 2. Physician support of HPV vaccination school-entry requirements (N D 775).
“Some states are trying to pass
laws that would require all 11 and
12 year-olds to get HPV vaccine
before they are allowed to start sixth grade.” “I think these laws are a good idea.”
Agree (%)
Neither agree nor
disagree (%)
Disagree (%) Total (%)
Agree 163 (21) 65 (8) 139 (18) 367 (47)
“It is okay to have these laws only if parents can
opt out if they want to.”
Neither agree nor disagree 60 (8) 59 (8) 38 (5) 157 (20)
Disagree 143 (18) 16 (2) 92 (12) 251 (32)
Total 366 (47) 140 (18) 269 (35) 775 (100)
Note. 74% (nD570) of physicians agreed with some form of HPV vaccination school-entry requirement (47% [first column total; Response of “agree” to “I think these laws
are a good idea.”] + 8% [Response of “neither agree nor disagree” to “I think laws these laws are a good idea” and “agree” to “It is okay to have these laws only if
parents can opt out if they want to”] + 18% [Response of “disagree” to “I think laws these laws are a good idea” and “agree” to “It is okay to have these laws only if
parents can opt out if they want to”]). May not sum to totals because of rounding. HPVDhuman papillomavirus.
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Table 3. Correlates of physician support of HPV vaccination school-entry requirements (N D 775).
# of respondents who agreed with
the statement “I think these laws
are a good idea”/ Total in category (%) Bivariate OR (95% CI) Multivariable OR (95% CI)
Physician attitudes about HPV vaccines
Requirements for Tdap vaccine make HPV vaccine seem less important
Did not agree 50/198 (25) Ref Ref
Agree 316/577 (55) 3.58 (2.50-5.14) 3.33 (2.26-4.90)
Relative importance of HPV vaccine to physicians1
Less important 138/392 (35) Ref Ref
As or more important 228/383 (56) 2.71 (2.02-3.62) 2.30 (1.65-3.18)
Perceived relative importance of HPV vaccine to parents1
Less important 299/646 (46) Ref —
As or more important 67/129 (52) 1.25 (0.86-1.83) —
Quality of current HPV vaccine recommendation practices
Low 146/418 (35) Ref Ref
High 220/357 (62) 2.99 (2.23-4.01) 2.06 (1.45-2.93)
Used presumptive style for HPV vaccine recommendation
No 227/539 (42) Ref Ref
Yes 139/236 (59) 1.97 (1.44-2.69) 1.30 (0.95-1.81)
HPV vaccine conversations uncomfortablebecause of having to talk about sex
Did not agree 239/526 (45) Ref —
Agree 127/249 (51) 1.25 (0.92-1.69) —
Takes more time to discuss HPV vaccine1
No 147/338 (43) Ref —
Yes 219/437 (50) 1.31 (0.98-1.74) —
Pharmacists provision of HPV vaccine benefits adolescents past due
Did not agree 204/470 (43) Ref Ref
Agree 162/305 (53) 1.48 (1.11-1.97) 1.31 (0.95-1.81)
Physician characteristics
Sex
Male 256/525 (49) Ref —
Female 110/250 (44) 0.83 (0.61-1.12) —
Medical subspecialty
Pediatrics 195/410 (48) Ref —
Family medicine 171/365 (47) 0.97 (0.73-1.29) —
Years practicing medicine
<20 years 149/351 (42) Ref Ref
20 years 217/424 (51) 1.42 (1.07-1.89) 1.49 (1.09-2.04)
Patients ages 11-17 seen per week
<10 65/129 (50)
10-24 157/350 (45) 0.80 (0.54-1.20) —
25 144/296 (49) 0.93 (0.61-1.41) —
Practice characteristics
Private practice
Yes 306/650 (47) Ref —
No 60/115 (52) 1.26 (0.85-1.88) —
Number of physicians
1 48/115 (42) Ref —
2-4 135/283 (48) 1.27 (0.82-1.97) —
5-9 99/217 (46) 1.17 (0.74-1.85) —
10 84/160 (53) 1.54 (0.95-2.50) —
Vaccines provided that are financed by VFC
0-9% 138/290 (48) Ref —
10-49% 125/273 (46) 0.93 (0.67-1.30) —
50% 78/152 (51) 1.16 (0.78-1.72) —
Not sure 25/60 (42) 0.79 (0.45-1.38) —
Regularly stocks HPV vaccine
No 33/73 (45) Ref —
Yes 333/702 (47) 1.09 (0.67-1.78) —
Region
Northeast 82/184 (47) Ref —
Midwest 81/165 (49) 1.20 (0.89-1.59) —
South 128/274 (47) 1.09 (0.75-1.59) —
West 75/152 (49) 1.21 (0.79-1.86) —
Dismisses families who continue to refuse adolescent vaccines2
No 325/684 (48) Ref —
Yes 41/91 (45) 0.91 (0.58-1.41) —
Note. VFCDVaccines for Children program; HPVDhuman papillomavirus; Ref D Referent group; Dashes (–) indicate the variable was not included in the multivariable
model because it was not statistically significant at the bivariate analysis.
1Relative to Tdap and meningococcal vaccines
2Clinics with a ‘yes’ answer have a policy that may dismiss patients or families if they continue to refuse any or all of the following vaccines: Tdap, meningococcal, HPV.
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vaccine recommendation quality, which may over- or under-
estimate the frequency of these practices. The study had a mod-
est response rate, which is a common challenge in physician
surveys. As we studied only pediatricians and family physicians,
we do not know whether the findings are generalizable to other
physicians who provide HPV vaccine such as gynecologists;
and we do not know how other important members of primary
care, such as nurse practitioners and physician assistants,
would view these requirements.
Conclusion
Voluntary school-located provision of HPV vaccine has
quickly led to impressive coverage in other developed coun-
tries,37,38 but this approach has been challenging in the US.
Alternatively, some US experts continue to consider school-
entry requirements. One line of thinking is that HPV vacci-
nation school-entry requirements are not for general use,
but instead that they are best for states that have already
achieved high vaccination rates, like Rhode Island which is
the state to most recently adopt a requirement. Another
suggestion has been that shifting vaccine policymaking from
a purely legislative process to one involving health officials,
as allowed by health codes in many states, might engender
more public trust and support.39 In the present study,
nearly 3 quarters of primary care providers supported some
form of school-entry requirement for HPV vaccination
among 11 and 12 y olds. Thus, physicians expressing gen-
eral opposition to the requirements in any form was
uncommon. Support correlated with high quality of current
HPV vaccine practices, high value placed on the vaccine,
recognition of the role of policy in vaccine messaging, and
years of experience. Further research is needed to investi-
gate the extent to which opt-out provisions might weaken
or strengthen support of school-entry requirements on
HPV vaccination among health care professionals.
Materials and methods
Participants and procedures
Study participants were members of an existing national panel
of physicians, maintained by a survey research company.40 The
current study was limited to pediatricians and family physi-
cians who provided preventive care, including vaccination, to
adolescent patients ages 11-12. From April to June 2014, the
survey research company sent invitations to 2,368 panel mem-
bers who met preliminary eligibility criteria. Of the physicians
invited, 1,022 (43%) accessed the survey site, 776 (76%) of
whom met eligibility criteria and completed the survey. After
excluding one participant who did not provide data on the out-
come variable, the final analytic sample consisted of 775 physi-
cians. Respondents provided informed consent and completed
the survey online. They received compensation of $25 to $45
for taking the survey, with higher amounts paid toward the end
of the study to encourage participation. The University of
North Carolina Institutional Review Board approved the study
protocol.
Measures
Support for school-entry requirements
The survey introduced the concept of school-entry requirement
for HPV vaccination with this text, “Some states are trying to
pass laws that would require all 11 and 12 year-olds to get HPV
vaccine before they are allowed to start 6th grade.” The first
survey item assessed support for school-entry requirements
without mention of an opt-out provision: “I think these laws
are a good idea.” The second item specifically mentioned an
opt-out provision: “It is okay to have these laws only if parents
can opt out if they want to.” The language used in these 2 items
matched previous survey measures assessing support for HPV
vaccination school-entry requirements among parents.17-18
Both items used 5-point response scales. We dichotomized
responses as agreeing (strongly agree or somewhat agree) and
not agreeing (strongly disagree, somewhat disagree, or neither
agree nor disagree).
Correlates
The survey assessed HPV vaccine recommendation quality on
the following dimensions: gender-specific timeliness, consis-
tency, urgency, and strength of endorsement. Timeliness was
assessed by questions regarding the age at which the provider
currently recommends HPV vaccine to males (before or after
age 13) and to females (before or after age 13). Consistency was
assessed by whether physicians used a risk-based approach,
rather than the recommended age-based approach, to selec-
tively recommend HPV vaccine. Urgency was assessed by
whether physicians recommended HPV vaccine at the current
visit, versus at a later visit. Lastly, strength of endorsement was
assessed by physician self-report of importance of HPV vaccine
for 11- to 12- year olds on a 5-point response scale that ranged
from not important to extremely important. We used the
approach of Gilkey and colleagues41 to combine these 5 items
to create an overall index of recommendation quality by award-
ing one point for each indicator of quality. Following Gilkey
et al.,41 we classified scores of 0-3 as “low quality” and 4-5 as
“high quality.”
To evaluate perceived importance of HPV vaccine require-
ments relative to a vaccine with established school-entry
requirement, the survey assessed agreement with the statement:
“Having a school-entry requirement for Tdap vaccine, but not
for HPV vaccine, makes some parents think HPV vaccine is
less important.” This item had a 5-point response scale, ranging
from strongly disagree to strongly agree, which we dichoto-
mized to reflect agreement or lack of agreement with the state-
ment. The survey also assessed importance of HPV vaccination
with the following statement: “When I recommend HPV vac-
cine for 11-12 y olds, I say it is…,” with a response scale that
ranged from not important to extremely important. The survey
repeated the same statement for meningococcal and Tdap vac-
cines. We calculated relative vaccine importance, giving a score
of 1 when physicians rated HPV vaccine as important as, or
more important than, the average score for Tdap and meningo-
coccal vaccines and 0 otherwise.
The survey assessed the time physicians reported needing
to talk to 11-12 y olds about the 3 vaccines. We calculated
whether it took more time to recommend HPV vaccine
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when compared to Tdap and meningococcal vaccines, or
the same or less time. The survey also assessed physicians’
vaccine recommendation style. We coded responses as “pre-
sumptive” if physicians began the conversation about HPV
vaccine by saying the child was due, rather than soliciting
questions or offering information first. The survey assessed
physician discomfort with the conversation about HPV vac-
cination with 2 questions, one asking generally if physicians
anticipated an uncomfortable conversation when recom-
mending HPV vaccine, and another which specifically asked
whether having to talk about sexually transmitted infections
made conversations about HPV vaccine uncomfortable. The
survey also assessed support for pharmacist provision of
HPV vaccines with the statement “It benefits 13-17 y olds
who are past due for HPV vaccine to receive it from spe-
cially trained pharmacists.”
The survey assessed physicians’ sex, medical specialty, years
in practice since residency training, region where they practice
medicine (based on US Census classifications), practice setting
(private practice vs. other), number of clinicians in the clinic,
number of adolescent patients seen in a typical week, and the
percentage of vaccine doses provided through the federally-
funded VFC program that provides free vaccines to under-
served populations.
Data analyses
We calculated proportions for the primary (“these laws are a
good idea”) and secondary (inclusion of opt-out provisions)
outcome variables and by participants’ characteristics and atti-
tudes about the vaccine. We calculated odds ratios (ORs) and
95% confidence intervals (CIs) using bivariate logistic regres-
sion to examine correlates of support for school-entry require-
ments. We then entered variables that were statistically
significant (P < .05) into a multivariable regression model.
Analyses used SAS version 9.4 (Cary, NC) and used 2-tailed
tests with a critical a of 0.05.
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